Atenolol in essential hypertension

Abstract

The effect of atenolol, a beta adrenoceptor autogonist, on arterial pressure in patients with benign essential hypertension has been investigated. Eighteen patients were started on atenolol, 75 mg/day; the dose was increased at 2-wk intervals to a maximum of 900 mg if tolerated. When the maximum effective dose was determined, each patient was randomly allocated into a double-blind crossover study comparing atenolol and placebo treatments. The mean supine and erect arterial pressures of the 16 patients completing the run-in period were markedly reduced by atenolol therapy. The pretreatment mean (+/-SEM) supine and erect arterial pressures of the 16 patients completing the run-in period (187 +/-4.7/114 +/-2.6 and 182 +/-4.5/115 +/-3.0 mm Hg, respectively) were reduced (150 +/-5.3/97 +/-2.9 and 151 +/-5.9/100 +/-2.7 mm Hg) with atenolol therapy (p less than 0.01). In the crossover study, the mean (+/-SEM) supine arterial pressure after 8 wk of atenolol therapy in 14 patients (144 +/-5.2/89 +/-1.7 mm Hg) was lower (p less than 0.01) than at the end of placebo therapy (163 +/-4.4/105 +/-2.8 mm Hg). Similar reductions in pressure were recorded in the erect position and after exercise. No severe side effects were observed.